FIVE YEAR BUDGET IMPACT ANALYSIS OF BIOSIMILAR INFLIXIMAB (CT-P13) FOR THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN SPAIN

2016 ◽  
Author(s):  
Seong-Hee Han
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis

scholarly journals Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

2020 ◽  
Vol 23 (11) ◽  
pp. 1302-1310
Author(s):  
Pochamana Phisalprapa ◽  
Chayanis Kositamongkol ◽  
Julajak Limsrivilai ◽  
Satimai Aniwan ◽  
Phunchai Charatcharoenwitthaya ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Cost Effectiveness ◽  
Crohn's Disease ◽  
Real World ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Real World Evidence
Sign in / Sign up

Export Citation Format

Share Document